Press Release Details

David J. Mazzo, PhD, President and CEO of Caladrius Biosciences, recorded a brief video presentation summarizing the proxy statement/prospectus (S-4) pertaining to the proposed merger with Cend Therapeutics. To view the presentation, please visit: https://youtu.be/P15Vdw-uVDc